ListaDAO launches new version of Smart Lending: comprehensive UI and data dashboard upgrade, enhancing lending transparency and user control
BlockBeats news, on March 19, according to official sources, ListaDAO officially announced the launch of Lista Smart Lending version 1.1. This upgrade brings a complete user interface (UI) overhaul and introduces a series of new features, aiming to provide users with greater transparency and enhanced lending management capabilities. By integrating key data and optimizing the interactive experience, Smart Lending 1.1 further simplifies the DeFi lending process, allowing users to intuitively grasp market trends and their own asset performance.
On the functional level, Smart Lending 1.1 introduces a brand-new "integrated market dashboard," which centralizes core information from both lending and trading markets. Users can view all available market overviews, pool types (currently focusing on stable pools, with future expansion to V2 and V3 pools), total value locked (TVL), 24-hour trading volume, and real-time annual percentage yield (APY) in one place. Additionally, each market is equipped with richer statistical data and visual charts, helping users gain deeper insights into liquidity conditions and yield structures, enabling decision-making without switching between multiple pages.
Meanwhile, this version also launches a brand-new "personal asset dashboard," providing users with a unified investment view. After connecting their wallet, users can view in real time the active markets they participate in, the current value of their holdings, detailed information on various liquidity and lending positions, as well as their share ratios in different pools, allowing for more precise evaluation of returns. The system also aggregates users' cumulative profit performance, enabling both novice and experienced DeFi participants to efficiently manage assets from a single interface. ListaDAO stated that further backend architecture upgrades will be promoted in the future to create a more unified and efficient lending experience.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly

XRP Ledger adds account control feature, enabling enterprises to manage assets offline.

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
